Comprehensive multigene mutation spectra of breast cancer patients from Northeast China obtained using the Ion Torrent sequencing platform

Fan,Chunni; Liu,Ning; Fan,Shulin; Yang,Zhaoying; Ye,Ning; Wang,Keren

doi:10.3892/or.2019.7253

October-2019 Volume 42 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October-2019 Volume 42 Issue 4

Full Size Image

Article

Comprehensive multigene mutation spectra of breast cancer patients from Northeast China obtained using the Ion Torrent sequencing platform

Authors:
- Chunni Fan
- Ning Liu
- Shulin Fan
- Zhaoying Yang
- Ning Ye
- Keren Wang
View Affiliations / Copyright

Affiliations: Department of Breast Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Wuhan PrimBio Medical Laboratory, PrimBio Gene Biotechnology, Wuhan, Hubei 430000, P.R. China
Pages: 1580-1588
|
Published online on: July 30, 2019

https://doi.org/10.3892/or.2019.7253
Expand metrics +

Abstract

The objectives of the present study were to obtain the multigene mutation spectra of female breast cancer patients in Northeast China, to explore the correlation between mutations and clinicopathological characteristics, and to identify genetic mutations that correlate with the prognosis and survival of breast cancer patients. An Ion Torrent sequencing platform was used to detect mutations, including 31 known gene mutations associated with breast cancer, in 621 specimens from 286 breast cancer patients. A total of 286 patients were enrolled in this study. Eleven harmful/pathogenic gene mutations were found in 54.2% (155/286) of the patients, and 179 somatic nonsynonymous mutations were detected. Approximately 5.6% (16/286) of the patients carried two or more gene mutations. Among the 11 pathogenic gene mutations, those in PIK3CA were the most common and were detected in 65.4% (117/179) of the patients; TP53 gene mutations were the second most common and were detected in 20.7% (37/179) of the patients. Additional mutations were found in AKT (14/179; 7.8%) and PTEN (4/179; 2.2%), and mutations in the remaining 7 genes were each detected in approximately 0.6% (1/179) of the patients. Excluding 6 cases of breast ductal carcinoma in situ, the remaining 280 breast cancer cases were divided into four groups by molecular subtype, and the mutation frequencies of the 11 breast cancer‑associated genes differed among the four groups. Furthermore, these 280 breast cancer cases were divided into two clinically relevant therapeutic groups: the HR+/HER2‑ and triple‑negative groups. The triple‑negative group had a high frequency of TP53 mutations (21.8%) and a low frequency of PIK3CA mutations (21.8%), whereas the HR+/HER2‑ group harbored TP53 mutations at a low frequency (10.1%) and PIK3CA mutations at a high frequency (50.0%). Cancerous, paracancerous, and normal tissues were collected from 72 patients and subjected to next‑generation sequencing. The types and frequencies of somatic nonsynonymous mutations differed among the three studied tissue types, reflecting the genetic heterogeneity of different tissues from the same individual. In addition, tissues from 70 patients (excluding 2 patients with ductal carcinoma in situ) were divided into four groups according to molecular subtype, and the gene mutation frequencies in cancerous, paracancerous, and normal tissues differed among the four groups. After normalization, gene mutations were detected at a higher rate in cancerous tissues than in paracancerous and normal tissues in all groups, except for the HER2‑positive group (which had a small sample size). In addition, Cox multivariate analyses of clinicopathological data, gene sequencing results, and 5‑year survival rates of the 286 patients showed that gene mutations in the PTEN‑PI3K/AKT signaling pathway were independently associated with a poor prognosis (P<0.05). In conclusion, mutations in the PTEN‑PI3K/AKT signaling pathway may be valuable in the prediction of the prognosis and survival of breast cancer patients.

View Figures

View References

1	Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D and Soerjomataram I: Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer. 51:1164–1187. 2015. View Article : Google Scholar : PubMed/NCBI
2	Brenner DR, Brockton NT, Kotsopoulos J, Cotterchio M, Boucher BA, Courneya KS, Knight JA, Olivotto IA, Quan ML and Friedenreich CM: Breast cancer survival among young women: A review of the role of modifiable lifestyle factors. Cancer Causes Control. 27:459–472. 2016. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Gray JM, Rasanayagam S, Engel C and Rizzo J: State of the evidence 2017: An update on the connection between breast cancer and the environment. Environ Health. 16:942017. View Article : Google Scholar : PubMed/NCBI
5	Makarem N, Chandran U, Bandera EV and Parekh N: Dietary fat in breast cancer survival. Annu Rev Nutr. 33:319–348. 2013. View Article : Google Scholar : PubMed/NCBI
6	Brewer HR, Jones ME, Schoemaker MJ, Ashworth A and Swerdlow AJ: Family history and risk of breast cancer: An analysis accounting for family structure. Breast Cancer Res Treat. 165:193–200. 2017. View Article : Google Scholar : PubMed/NCBI
7	Zhang B, Shu XO, Delahanty RJ, Zeng C, Michailidou K, Bolla MK, Wang Q, Dennis J, Wen W, Long J, et al: Height and breast cancer risk: Evidence from prospective studies and mendelian randomization. J Natl Cancer Inst. 107:djv2192015. View Article : Google Scholar : PubMed/NCBI
8	Kwong A, Shin VY, Ho JC, Kang E, Nakamura S, Teo SH, Lee AS, Sng JH, Ginsburg OM, Kurian AW, et al: Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J Med Genet. 53:15–23. 2016. View Article : Google Scholar : PubMed/NCBI
9	Stadler ZK, Schrader KA, Vijai J, Robson ME and Offit K: Cancer genomics and inherited risk. J Clin Oncol. 32:687–698. 2014. View Article : Google Scholar : PubMed/NCBI
10	Smith DR, Quinlan AR, Peckham HE, Makowsky K, Tao W, Woolf B, Shen L, Donahue WF, Tusneem N, Stromberg MP, et al: Rapid whole-genome mutational profiling using next-generation sequencing technologies. Genome Res. 18:1638–1642. 2008. View Article : Google Scholar : PubMed/NCBI
11	Gilissen C, Hehir-Kwa JY and Thung DT: Genome sequencing identifies major causes of severe intellectual disability. Nature. 511:344–347. 2014. View Article : Google Scholar : PubMed/NCBI
12	Kittaneh M, Montero AJ and Gluck S: Molecular profiling for breast cancer: A comprehensive review. Biomark Cancer. 5:61–70. 2013. View Article : Google Scholar : PubMed/NCBI
13	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ; Panel members, : Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
14	Marziali A and Akeson M: New DNA sequencing methods. Annu Rev Biomed Eng. 3:195–223. 2001. View Article : Google Scholar : PubMed/NCBI
15	Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, Li F, Tsang S, Wu K, Wu H, et al: Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell. 148:886–895. 2012. View Article : Google Scholar : PubMed/NCBI
16	Hou Y, Song L, Zhu P, Zhang B, Tao Y, Xu X, Li F, Wu K, Liang J, Shao D, et al: Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell. 148:873–885. 2012. View Article : Google Scholar : PubMed/NCBI
17	Clinical and laboratory standards institute, . Nucleic acid sequencing methods in diagnostic laboratory medicine. Approved guideline-Second Edition CLSI document MM09. A2. (Wayne, PA). CLSI. 2014.
18	Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 360:790–800. 2009. View Article : Google Scholar : PubMed/NCBI
19	Roukos D and Ku CS: Clinical cancer genome and precision medicine. Ann Surg Oncol. 19:3646–3650. 2012. View Article : Google Scholar : PubMed/NCBI
20	Damerla RR, Chatterjee B, Li Y, Francis RJ, Fatakia SN and Lo CW: Ion Torrent sequencing for conducting genome-wide scans for mutation mapping analysis. Mamm Genome. 25:154–156. 2014. View Article : Google Scholar
21	Meldrum C, Doyle MA and Tothill RW: Next-generation sequencing for cancer diagnostics: A practical perspective. Clin Biochem Rev. 32:177–195. 2011.PubMed/NCBI
22	Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
23	Almendro V and Fuster G: Heterogeneity of breast cancer: Etiology and clinical relevance. Clin Transl Oncol. 13:767–773. 2011. View Article : Google Scholar : PubMed/NCBI
24	Fujita S, Masago K, Takeshita J, Okuda C, Otsuka K, Hata A, Kaji R, Katakami N and Hirata Y: Validation of an Ion Torrent sequencing platform for the detection of gene mutations in biopsy specimens from patients with non-small-cell lung cancer. PLoS ONE. 10:e01302192015. View Article : Google Scholar : PubMed/NCBI
25	Zanella I, Merola F, Biasiotto G, Archetti S, Spinelli E and Di Lorenzo D: Evaluation of the Ion Torrent PGM sequencing workflow for the routine rapid detection of BRCA1 and BRCA2 germline mutations. Exp Mol Pathol. 102:314–320. 2017. View Article : Google Scholar : PubMed/NCBI
26	Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, et al: Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 144:713–721. 2015. View Article : Google Scholar : PubMed/NCBI
27	Bai X, Zhang E, Ye H, Nandakumar V, Wang Z, Chen L, Tang C, Li J, Li H, Zhang W, et al: PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing. PLoS One. 9:e993062014. View Article : Google Scholar : PubMed/NCBI
28	Klarenbeek S, van Miltenburg MH and Jonkers J: Genetically engineered mouse models of PI3K signaling in breast cancer. Mol Oncol. 7:146–164. 2013. View Article : Google Scholar : PubMed/NCBI
29	Samuels Y and Waldman T: Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 347:21–41. 2010.PubMed/NCBI
30	Bhat-Nakshatri P, Goswami CP, Badve S, Magnani L, Lupien M and Nakshatri H: Molecular insights of pathways resulting from two common PIK3CA mutations in breast cancer. Cancer Res. 76:3989–4001. 2016. View Article : Google Scholar : PubMed/NCBI
31	Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, Tabone E, Puisieux A and Wang Q: Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat. 132:29–39. 2012. View Article : Google Scholar : PubMed/NCBI
32	Tserga A, Chatziandreou I, Michalopoulos NV, Patsouris E and Saetta AA: Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. Virchows Arch. 469:35–43. 2016. View Article : Google Scholar : PubMed/NCBI
33	Lee MS, Jeong MH, Lee HW, Han HJ, Ko A, Hewitt SM, Kim JH, Chun KH, Chung JY, Lee C, et al: PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis. Nat Commun. 6:77692015. View Article : Google Scholar : PubMed/NCBI
34	Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
35	Koundouros N and Poulogiannis G: Phosphoinositide 3-kinase/Akt signaling and redox metabolism in cancer. Front Oncol. 8:1602018. View Article : Google Scholar : PubMed/NCBI
36	Miller TW, Rexer BN, Garrett JT and Arteaga CL: Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 13:2242011. View Article : Google Scholar : PubMed/NCBI
37	Papadavid E, Korkolopoulou P, Levidou G, Saetta AA, Papadaki T, Siakantaris M, Nikolaou V, Oikonomidi A, Chatziandreou I, Marinos L, et al: In situ assessment of PI3K and PTEN alterations in mycosis fungoides: Correlation with clinicopathological features. Exp Dermatol. 23:931–933. 2014. View Article : Google Scholar : PubMed/NCBI
38	Bozhanov SS, Angelova SG, Krasteva ME, Markov TL, Christova SL, Gavrilov IG and Georgieva EI: Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol. 136:1657–1669. 2010. View Article : Google Scholar : PubMed/NCBI
39	Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, et al: The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 7:114792016. View Article : Google Scholar : PubMed/NCBI
40	Kato T, Park JH, Kiyotani K, Ikeda Y, Miyoshi Y and Nakamura Y: Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. Oncotarget. 8:62029–62038. 2017. View Article : Google Scholar : PubMed/NCBI
41	Kim JY, Lee E, Park K, Park WY, Jung HH, Ahn JS, Im YH and Park YH: Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes. Oncotarget. 8:27997–28007. 2017.PubMed/NCBI
42	Yang X, Wu J, Lu J, Liu G, Di G, Chen C, Hou Y, Sun M, Yang W, Xu X, et al: Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing. PLoS One. 10:e01255712015. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Comprehensive multigene mutation spectra of breast cancer patients from Northeast China obtained using the Ion Torrent sequencing platform

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles